Advances in prostate cancer biomarker research

**Location:** Room Madrid (Hall B2, level 0)

**Chairs:** M. Lazzeri, Florence (IT)  
H.G. Lilja, New York (US)  
T. Steuber, Hamburg (DE)

**Aims and objectives of this presentation**
There is an increasing interest in the role of truncated androgen receptors in prostate cancer. These potentially very important biomarkers have been identified in several publications, however scientific consensus has to be reached. In addition, controversies on activated transcription factors as biomarkers will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

**16:08 - 16:18**

**Prostate cancer biomarkers: What’s new?**  
H.G. Lilja, New York (US)

*1064**

**Delivery of precision medicine in advanced prostate cancer using circulating tumour cells**
By: Rhee H.¹, Gunter J.², Javanovic L.², Williams E.², Hollier B.², Nelson C.², Vela l.³

**Institutes:** Princess Alexandra Hospital/Queensland University of Technology, Dept. of Urology and Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia. ²Queensland University of Technology, Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia

*1065**

**Detection of AR-V7 in circulating tumour cells before ADT is a negative prognostic marker in castration-naïve men with metastatic prostate cancer**
By: Josefsson A., Damber J-E., Welén K.

**Institutes:** Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Dept. of Urology, Gothenburg, Sweden

*1067**

**SIK2 is a novel secreted protein associated with a malignant phenotype in prostate cancer**
By: Wadhwa K.¹, Bon H.², Holmes K.³, Warren A.⁴, Whittaker H.⁵, Kay J.⁵, Fryer L.², Neal D.², Gnanapragasam V.¹, Carroll J.³

**Institutes:** Academic Urology Group, Dept. of Urology, Cambridge, United Kingdom. ¹Neal Laboratory, Dept. of Uro-Oncology, Cambridge, United Kingdom. ²Carroll Laboratory, Cambridge Institute CRUK, Cambridge, United Kingdom. ³Addenbrooke’s Trust University of Cambridge, Dept. of Pathology, Cambridge, United Kingdom. ⁴Biomarker Group, Cambridge Institute CRUK, Cambridge, United Kingdom

*1068**

**Expression of pSTAT3 in prostate cancer metastases from different organs**
By: Don-Doncow N.¹, Marginean F.¹, Morrissey C.², Hellsten R.¹, Bjartell A.¹

**Institutes:** Lund University Hospital, Dept. of Translational Medicine Malmö, Malmö, Sweden. ²University of Washington, Dept. of Urology, Seattle, United States of America

*1069**

**Intratumoral heterogeneity of mTOR-pathway parameters in prostate cancer**
By: Schanz M.¹, Hennenlotter J.¹, Dlugosch J.¹, Kuehs U.¹, Dettmer M.², Schilling D.³, Schwentner C.¹, Stenzl A.¹, Todenhöfer T.¹

**Institutes:** Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany. ²Universitätsklinik Bern, Dept. of Pathology, Berne, Germany. ³Isar Klinikum, Dept. of Urology, Munich, Germany
Poster Session 84

*1070

Regenerating islet-derived related protein 4 as candidate of a novel biomarker in castration-resistant prostate cancer patients

By: Teishima J.¹, Nagamatsu H.¹, Shoji K.¹, Yamanaka R.¹, Kobatake K.¹, Kitano H.¹, Goto K.¹, Shimmei S.¹, Hayashi T.¹, Oue N.², Yasui W.², Matsubara A.¹

Institutes: Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan

*1071

The role of genomic classifier to assess post-operative metastatic risk for prostate cancer patients based on final pathology characteristics

By: Woodlief T.L., Rocco B., Ramharack R., Gnapathi H., Ogaya G., Mouravieve V., Patel V.

Institutes: Florida Hospital, Global Robotics Institute, Celebration, United States of America

*1072

A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer

By: Heck M.¹, Thalgott M.¹, Schmid S.¹, Oh W.², Gong Y.², Wang L.², Zhu J.³, Seitz A-K.¹, Porst D.¹, Höppner M.¹, Retz M.¹, Gschwend J.¹, Nawroth R.¹

Institutes: Klinikum Rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany, ²Mount Sinai Hospital, The Tisch Cancer Institute, Dept. of Hematology/Oncology, New York, United States of America, ³Mount Sinai Hospital, The Tisch Cancer Institute, Dept. of Genetic and Genomic Sciences, New York, United States of America

*1073

Prostate cancer copy number score predicts metastatic disease

By: Van Den Broeck T.¹, Gevaert T.¹, Prekovic S.², Smeets E.², Helsen C.², Lambrechts D.³, Boeckx B.³, Joniau S.¹, Claessens F.²

Institutes: University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium, ³KU Leuven, Laboratory For Translational Genetics, Vesalius Research Center, VIB, Leuven, Belgium

*1074

Microseminoprotein-beta expression in different stages of prostate cancer

By: Sjöblom L², Saramäki O.², Annala M.², Leinonen K.², Näätänen J.², Tolonen T.³, Wahlfors T.², Nykter M.², Bova G.², Schleutker J.⁴, Tammela T.¹, Lilja H.², Visakorpi T.²

Institutes: ¹Tampere University Hospital, Dept. of Surgery, Tampere, Finland, ²University of Tampere, BioMediTech, Tampere, Finland, ³Fimlab Laboratories, Dept. of Pathology, Tampere, Finland, ⁴University of Turku, BioMediTech, Tampere, Finland

*1075

PD-L1 expression in castration-resistant prostate cancer (CRPC)

By: Fankhauser C.¹, Schüffler P.², Gillessen S.³, Omlin A.³, Hermanns T.¹, Poyet C.⁴, Sulser T.¹, Moch H.⁴, Wild P. J.⁴

Institutes: ¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²Memorial Sloan Kettering Cancer Center, The Thomas Fuchs Lab, New York, United States of America, ³Cantonal Hospital, St. Gallen, Dept. of Medical Oncology and Hematology, St. Gallen, Switzerland, ⁴University Hospital Zurich, Institute of Surgical Pathology, Zurich, Switzerland